Background. We measured the effect of low-level fluoroquinolone resistance in Streptococcus pneumoniae on the development of high-level resistance within the context of the mutant selection window. Methods. Rabbits infected with S. pneumoniae were treated with ciprofloxacin or moxifloxacin concentrations that simulated pharmacokinetics in treated humans; bacteria obtained from lungs were examined for fluoroquinolone susceptibility. Results. Ciprofloxacin enriched resistant mutants from a wild-type strain; moxifloxacin did not. However, moxifloxacin enriched resistant mutants from a parC mutant; the drug concentration at the top of the selection window was determined. Conclusions. A parC resistance mutation facilitates the enrichment of high-level resistance, as was predicted by in vitro measurements.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Infectious Diseases|
|State||Published - Oct 15 2004|
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Infectious Diseases